Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Neuroblastoma 11Brain Neoplasms 3Recurrence 2Osteosarcoma 2Multiple Myeloma 2Medulloblastoma 2Leukemia, Myeloid, Acute 2Glioma 2Glioblastoma 2Diffuse Intrinsic Pontine Glioma 2Xanthomatosis, Cerebrotendinous 1Vaccinia 1Uveal Melanoma 1Transplant-Related Hematologic Malignancy 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Resectable Esophageal Cancer 1Prostatic Neoplasms 1Pathologic Complete Response 1Oligodendroglioma 1Neoplasms 1Melanoma 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Liver Neoplasms 1Leukemia 1Kidney Neoplasms 1Influenza, Human 1

Interventions

Rituximab 85Cyclophosphamide 80Prednisone 47Doxorubicin 43Lenalidomide 36Vincristine 34Magnetic Resonance Spectroscopy 29polatuzumab vedotin 28Gemcitabine 26Etoposide 26Specimen Handling 25fludarabine 23Biopsy 21Oxaliplatin 20CT-P10 20glofitamab 16tafasitamab 15obinutuzumab 15ibrutinib 13fludarabine phosphate 13zanubrutinib 12axicabtagene ciloleucel 12Immunotherapy, Adoptive 12Ifosfamide 12venetoclax 11pembrolizumab 11deltacortene 11prednylidene 10Prednisolone 10Leukapheresis 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Large B-Cell, Diffuse × Granulocyte-Macrophage Colony-Stimulating Factor × 1 year × Clear all
NCT06651853 2025-07-23

Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL

The First Affiliated Hospital of Xiamen University

Phase 2 Recruiting
22 enrolled
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡